A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone
Ontology highlight
ABSTRACT: Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart disease and has been observed in diabetic patients treated with rosiglitazone, whereas most published studies do not suggest a similar increase in risk of cardiovascular events in pioglitazone-treated diabetic subjects. This study sought to understand the pathophysiological mechanisms underlying the disparate cardiovascular effects of rosiglitazone and pioglitazone and yield knowledge as to the causative nature of rosiglitazone-associated cardiac hypertrophy.
ORGANISM(S): Mus musculus
PROVIDER: GSE48977 | GEO | 2014/06/30
SECONDARY ACCESSION(S): PRJNA212503
REPOSITORIES: GEO
ACCESS DATA